Episodic migraine
Drug research and approvals for episodic migraine: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 28 studies of episodic migraine are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 28
- Trials authorized in Canada: 12
- FDA orphan approvals: 0
- EU medicines: 1
- A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant MigraineNCT07719608 · Not applicable · Salvia BioElectronics · starts Dec 1, 2026
- Online Hatha Yoga Program as an Add-On Therapy for Episodic High-Frequency MigraineNCT07694063 · Not applicable · University of Seville · starts Jan 27, 2026
- Study of EVO756 in Adults With MigraineNCT07616128 · Phase 2 · Evommune, Inc. · starts Jul 29, 2026
- Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With PhenotypesNCT07518069 · Not reported · IRCCS San Raffaele · starts Apr 9, 2025
- Efficacy of Gou-Teng-San (GTS) in Patients With Episodic MigraineNCT07496034 · Phase 3 · Tsai, Chueh-Yi, MD · starts Jul 1, 2025
- Yogabased Movements for Primary Headaches (Migraine and/or Cluster Headache) - YOURHEADNCT07348783 · Not applicable · Karolinska Institutet · starts May 1, 2026
- PERSONOLOGICAL STRUCTURE, COGNITIVE FUNCTIONS AND CENTRAL SENSITIZATION IN HEADACHENCT07268768 · Not reported · IRCCS Centro Neurolesi Bonino Pulejo · starts Nov 20, 2025
- Real-world Prospective Study on the Use of Anti-CGRP Drugs in MigraineNCT07159750 · Not reported · Hospital Universitari Vall d'Hebron Research Institute · starts Jan 2, 2024
- i-NEED: NEw migrainE Drugs DatabaseNCT07103694 · Not reported · IRCCS San Raffaele Roma · starts Mar 24, 2022
| Sep 10, 2025 | A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in…IPN10200 | Ipsen | Ongoing |
| Jul 16, 2025 | A phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of xeomin®…Xeomin | Merz Therapeutics GmbH | Ongoing |
| Aug 29, 2023 | A phase III, randomised, double-blind, placebo-controlled, multicentre, parallel-group study with extension phase to evaluate the efficacy and safety of…Dysport (IPN52120) | Ipsen | Ongoing |
| Jun 23, 2023 | Interventional, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of intravenous (IV) eptinezumab in…Eptinezumab | H. Lundbeck A/S | Ongoing |
| Mar 21, 2023 | A phase 3, multicenter, 12-week, double blind, placebo-controlled study to evaluate the safety and efficacy of atogepant for the preventive treatment of…Atogepant | AbbVie | Ongoing |
| Mar 4, 2022 | Long term, open label (dose blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraineEptinezumab | H. Lundbeck A/S | Ongoing |
| Jan 22, 2021 | A phase 3, multicenter, open-label 156-week extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine…Atogepant | AbbVie | Closed |
| Jan 11, 2021 | A phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of oral atogepant…Atogepant | AbbVie | Closed |
| Nov 10, 2020 | Randomized, double-blind, placebo-controlled study of fremanezumab in patients (6 to 17 years) with episodic migraineAjovy | Teva Pharmaceutical Industries | Ongoing |
| Nov 9, 2020 | A multicenter, open-label study evaluating long-term safety, tolerability, and efficacy of monthly subcutaneous administration of fremanezumab for the…Ajovy (fremanezumab) | Teva Pharmaceutical Industries | Ongoing |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Apr 25, 2022 | VyduraRimegepant | Pfizer Europe MA EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA